Adaptive biotechnologies stock.

Dec 1, 2022 · SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ... DOI: 10.1200/JCO.21.00377 Journal of Clinical Oncology - published online before print June 16, 2021 . PMID: 34133196Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79.A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Nov 30, 2023 · The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies. 52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.

At present, SG Americas Securities LLC holds a total of 76,854 shares of Adaptive Biotechnologies Co., compared to its previous ownership of 28,962 shares. The acquisition of an additional 47,892 shares during the first quarter highlights the firm’s belief in the long-term prospects and value of Adaptive Biotechnologies’ stock.

Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ADPT Edit my quotes Adaptive Biotechnologies Corporation Common...Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ...What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.

Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.

View today's Adaptive Biotechnologies Corp stock price and latest ADPT news and analysis. Create real-time notifications to follow any changes in the live stock price.

Taking the right travel adapter with you will ensure you're never without — but with so many types, it can be tricky to know what you need. We may be compensated when you click on product links, such as credit cards, from one or more of our...Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20.Adaptive Biotechnologies Corporation (ADPT) Stock Price, Quote & News - Stock Analysis Adaptive Biotechnologies Corporation ( ADPT) Watchlist 4.37 +0.12 …Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30 …Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Adaptive Biotechnologies. Cathie Wood has bought almost 10 million shares of this stock for her Ark Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage ...

Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look ...SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ...Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Dec 3, 2023 · 2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ... Get the latest Adaptive Biotechnologies Corp (ADPT) real-time quote, historical performance, charts, and other financial information to help you make more informed …

Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .

So consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ...The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …Adaptive Biotechnologies ( ADPT -9.24%) is a biotech-adjacent stock that peaked in January and then fell hard. It's down 61% from its high-water mark, but the average analyst on Wall Street thinks ...Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20.Adaptive Biotechnologies Corp is down 12.44% from its previous closing price of $7.96. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.87 and $8.10. Currently, there are 143.51 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s ...

In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by Institutions

Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ...

Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... Adaptive Biotechnologies ( ADPT -9.24%) is a biotech-adjacent stock that peaked in January and then fell hard. It's down 61% from its high-water mark, but the average analyst on Wall Street thinks ...Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. …Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ... Adaptive Biotechnologies. Wood has bought almost 10 million shares of this stock for her ARK Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage company ...Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. Date.Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives’ for key business lines With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct a review of strategic alternatives for its Minimal Residual Disease (MRD) and Immune Medicine …

Nov 29, 2023 · Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ... Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Adaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at MizuhoOn November 9, Adaptive Biotechnologies will report earnings from Q3. Wall Street analysts predict losses per share of $0.339. Track Adaptive Biotechnologies stock price in real-time ahead here ...Instagram:https://instagram. cigna preferred dental planzero sugar champagnemarc chaikin stock picks todaymozark fire pits Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. Webcast and Conference Call Information. Adaptive Biotechnologies will host a conference call to discuss its first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 4:30 PM Eastern Time.Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (ADPT 7.31%), Burning Rock Biotech (BNR-0.12%), or both. ... Get stock recommendations, portfolio ... dividend wells fargoprcox Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight … legalshield vs arag Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...Adaptive Biotechnologies is a biotechnology company that develops products based on the adaptive immune system. The web page provides stock …